UBS sets USD 16.00 target for Ultragenyx Pharmaceutical stock

Published on 10/17/2026 at 21:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 214.00 million in second-quarter 2026. Ultragenyx Pharmaceutical stock costs USD 14.54 on October 16, 2026, down 4.15 percent on Nasdaq.

UBS begins coverage

UBS Group initiated coverage on October 15, 2026 with a neutral rating and a USD 16.00 target.
Revenue reached USD 214.00 million in the second quarter of 2026.
Ultragenyx Pharmaceutical stock last traded at USD 14.54 on October 16, 2026 at 4:00 p.m. ET, down 4.15 percent versus the prior close.
Market capitalization was USD 1.4 billion and the price-to-earnings ratio was -2.49 on October 16, 2026.

RARE, US90400D1081, Illustration mit AI erstellt.

UBS Group began coverage of Ultragenyx Pharmaceutical on October 15, 2026, assigning a neutral rating and a USD 16.00 price target, according to MarketBeat. The target is 10.04 percent above the USD 14.54 Nasdaq price. On Nasdaq, Ultragenyx last traded at USD 14.54 on October 16, 2026 at 4:00 p.m. ET, minus 4.15 percent versus the prior close.

Revenue reached USD 214.00 million

Ultragenyx generated USD 214.00 million in revenue in the second quarter of 2026, up 28.50 percent from the year-earlier quarter, according to Yahoo Finance. The same report put the net loss at USD 92.00 million and diluted loss per share at USD 0.90. Revenue exceeded the cited consensus of USD 183.08 million, while the loss per share was narrower than the expected USD 1.22 loss.

Price sits 14.22 percent above the low

The October 16, 2026 Nasdaq price of USD 14.54 was 14.22 percent above the 52-week low of USD 12.73 and 63.55 percent below the 52-week high of USD 39.89. Trading volume reached 2,924,015 shares, compared with an average volume of 4,053,339 shares.

Market value and earnings multiple

Ultragenyx had a market capitalization of USD 1.4 billion and a price-to-earnings ratio of -2.49 on October 16, 2026. Its dividend yield was 0.00 percent. The company describes its business as developing treatments for rare and ultra-rare genetic diseases on its investor-relations site.

Comparison with peers

Ultragenyx Pharmaceutical (Nasdaq, USD): minus 4.15 percent, P/E -2.49, market capitalization USD 1.4 billion
BioMarin Pharmaceutical (Nasdaq, USD): minus 2.44 percent, P/E 140.21, market capitalization USD 10.6 billion
Sarepta Therapeutics (Nasdaq, USD): minus 3.88 percent, P/E -5.90, market capitalization USD 1.8 billion

What the valuation signals

Ultragenyx traded closer to its 52-week low than to its high, while the negative price-to-earnings ratio reflected its loss-making position on October 16, 2026. The UBS target provides a separate dated analyst reference at USD 16.00, 10.04 percent above the Nasdaq price.